Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Defendants Appeal Court Ruling on US Abilify Patent
January 3, 2011
- Hodanren, MIN-IREN Opposed to Premium for Development of New Drugs
January 3, 2011
- Nippon Kayaku Licenses Spanidin to Nordic Pharma Group
January 3, 2011
- NanoCarrier to Obtain Patents in Asia, Oceania
January 3, 2011
- MTPC, Novartis Apply for FTY720 in Japan
January 3, 2011
- Astellas Obtains Extended License on Seroquel ER Tab in Japan
January 3, 2011
- Mochida Ties Up with Gedeon Richter for Biosimilars
January 3, 2011
- Sanko Junyaku Acquires Marketing Rights for Flu Test Kit
January 3, 2011
- MTPC, Anaphore Agree to Jointly Develop Drugs for Autoimmune Diseases
January 3, 2011
- Nippon Kayaku to Lead Antibody Biosimilar Market in Japan: Nomura Securities Report
January 3, 2011
- Eisai Applies for Marketing Authorization for Embolic Beads
January 3, 2011
- Sanofi-aventis to Tie Up with Merck Serono in Oncology
January 3, 2011
- Taiyo Holds Meetings with Clients on GMP Compliance Measures
January 3, 2011
- ARBs Effective for Improving Albuminuria: DSP survey
January 3, 2011
- DSP Completes Merger of Chinese Subsidiaries
January 3, 2011
- US Generics Market to Outgrow New Drugs Market: IGPA Annual Conference
January 3, 2011
- Pfizer Applies for Solu-Medrol Based on Data from the Public Domain
January 3, 2011
- Shionogi, Wakamoto to Copromote Non-prescription Oral Care Products
January 3, 2011
- Apollo Medical to Expand Overseas Training Program for Its Employees
January 3, 2011
- FDA Recommends Withdrawal of Approval for Breast Cancer for Avastin
January 3, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…